Cargando…

Independent Adipogenic and Contractile Properties of Fibroblasts in Graves’ Orbitopathy: An In Vitro Model for the Evaluation of Treatments

Graves’ orbitopathy (GO) is a disfiguring and sometimes blinding disease, characterised by inflammation and swelling of orbital tissues, with fibrosis and adipogenesis being predominant features. Little is known about the disease aetiology and the molecular mechanisms driving the phenotypic changes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, He, Fitchett, Caroline, Kozdon, Katarzyna, Jayaram, Hari, Rose, Geoffrey E., Bailly, Maryse, Ezra, Daniel G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994071/ https://www.ncbi.nlm.nih.gov/pubmed/24751986 http://dx.doi.org/10.1371/journal.pone.0095586

Ejemplares similares

MicroRNA-27 inhibits adipogenic differentiation in orbital fibroblasts from patients with Graves’ orbitopathy
por: Jang, Sun Young, et al.
Publicado: (2019)

Macrophages promote a profibrotic phenotype in orbital fibroblasts through increased hyaluronic acid production and cell contractility
por: Yang, I-Hui, et al.
Publicado: (2019)

Graves' Orbitopathy
por: Hiromatsu, Yuji, et al.
Publicado: (2015)

Current Knowledge on Graves’ Orbitopathy
por: Gontarz-Nowak, Katarzyna, et al.
Publicado: (2020)

Teprotumumab: a disease modifying treatment for graves’ orbitopathy
por: Ting, Michelle, et al.
Publicado: (2020)

Asymmetric Graves’ Orbitopathy
por: Panagiotou, Grigorios, et al.
Publicado: (2020)

Significance of HLA in the development of Graves’ orbitopathy
por: Stasiak, Magdalena, et al.
Publicado: (2023)

ELF3-induced miR-182 inhibits adipogenic differentiation in Graves’ orbitopathy by targeting thyrotropin receptor
por: Wang, Sha, et al.
Publicado: (2023)

The Role of the Microbiota in Graves’ Disease and Graves’ Orbitopathy
por: Hou, Jueyu, et al.
Publicado: (2021)

Antioxidant Therapy in Graves’ Orbitopathy
por: Lanzolla, Giulia, et al.
Publicado: (2020)

Orbital Signaling in Graves’ Orbitopathy
por: Draman, Mohd Shazli, et al.
Publicado: (2021)

Graves’ orbitopathy occurs sex-independently in an autoimmune hyperthyroid mouse model
por: Schlüter, Anke, et al.
Publicado: (2018)

Graves’ disease and Graves’ orbitopathy following COVID-19
por: Lanzolla, G., et al.
Publicado: (2021)

Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

A Tenon’s capsule/bulbar conjunctiva interface biomimetic to model fibrosis and local drug delivery
por: Kozdon, Katarzyna, et al.
Publicado: (2020)

Novel Roles of Chloroquine and Hydroxychloroquine in Graves’ Orbitopathy Therapy by Targeting Orbital Fibroblasts
por: Guo, Yan, et al.
Publicado: (2020)

Association of fibroblast growth factor 10 with the fibrotic and inflammatory pathogenesis of Graves’ orbitopathy
por: Jang, Sun Young, et al.
Publicado: (2021)

Therapeutic Effect of Gypenosides on Antioxidant Stress Injury in Orbital Fibroblasts of Graves' Orbitopathy
por: Ma, Chao, et al.
Publicado: (2022)

Rituximab in the treatment of Graves’ orbitopathy: latest updates and perspectives
por: Supronik, Jakub, et al.
Publicado: (2022)

Tears as a Source of Biomarkers in the Diagnosis of Graves’ Orbitopathy
por: Bajkowska, Diana, et al.
Publicado: (2022)

Graves′ orbitopathy: Management of difficult cases
por: Wiersinga, Wilmar M.
Publicado: (2012)

Endoscopic orbital decompression for Graves’ orbitopathy
por: Lal, Priti, et al.
Publicado: (2013)

Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2020)

Current concepts regarding Graves’ orbitopathy
por: Bartalena, Luigi, et al.
Publicado: (2022)

Update on the surgical management of Graves’ orbitopathy
por: Baeg, Joonyoung, et al.
Publicado: (2023)

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement
por: Perros, P., et al.
Publicado: (2017)

Novel Insight into Non-Genetic Risk Factors of Graves’ Orbitopathy
por: Zawadzka-Starczewska, Katarzyna, et al.
Publicado: (2022)

Chemokine Expression during Adipogenesis and Inflammation in Orbital Fibroblasts from Patients with Graves' Orbitopathy
por: Lee, Chae Eun, et al.
Publicado: (2020)

Significance of HLA in Graves’ disease and Graves’ orbitopathy in Asian and Caucasian populations – a systematic review
por: Stasiak, Magdalena, et al.
Publicado: (2023)

Planning health care for patients with Graves’ orbitopathy
por: Sasim, Inna V., et al.
Publicado: (2008)

Surgical complications in orbital decompression for Graves' orbitopathy
por: Sellari-Franceschini, S., et al.
Publicado: (2016)

Mechanisms That Underly T Cell Immunity in Graves’ Orbitopathy
por: Fang, Sijie, et al.
Publicado: (2021)

Serum thyroglobulin is associated with orbitopathy in Graves’ disease
por: Khamisi, S., et al.
Publicado: (2021)

Correction to: Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2021)

Roles of four targets in the pathogenesis of graves' orbitopathy
por: Ren, Ziqiang, et al.
Publicado: (2023)

Atypical Asymmetric Presentation of Severe Graves’ Orbitopathy
por: Gupta, Priyanka, et al.
Publicado: (2023)

Therapeutic Effect of Guggulsterone in Primary Cultured Orbital Fibroblasts Obtained From Patients with Graves’ Orbitopathy
por: Kim, Bo Ram, et al.
Publicado: (2020)

SAT-421 Novel Role of Chloroquine and Hydroxychloroquine in Graves’ Orbitopathy Therapy by Targeting Orbital Fibroblasts
por: Guo, Yan, et al.
Publicado: (2020)

Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves’ Orbitopathy in Orbital Fibroblasts
por: Lee, Ga Eun, et al.
Publicado: (2021)

Disulfiram Exerts Antifibrotic and Anti-Inflammatory Therapeutic Effects on Perimysial Orbital Fibroblasts in Graves’ Orbitopathy
por: Wang, Xing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ffmvjdfi7q86qkm687ltssaia4